查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594470

神經診斷市場：按產品、適應症和最終用戶分類 - 全球預測 2025-2030

Neurodiagnostics Market by Product (Clinical Testing Instrument, Diagnostic & Imaging System, Reagent & Consumable), Indication (Epilepsy, Headache Disorder, Neurodegenerative Diseases), End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年神經診斷市場價值為73.4億美元，預計到2024年將達到79.7億美元，複合年成長率為8.71%，到2030年將達到131.8億美元。

神經診斷市場包括用於評估和監測神經系統疾病的診斷工具和測試的開發和使用。隨著阿茲海默症、癲癇和帕金森氏症等神經系統疾病的盛行率持續上升，對準確診斷方法的需求也隨之增加。該市場包括各種應用，例如醫療機構、診斷實驗室和學術研究中心的神經成像、體外診斷和神經資訊學。主要成長動力包括人口老化的加劇、神經影像技術的進步以及對微創診斷的需求不斷增加。人工智慧驅動的圖像分析和可攜式腦電圖設備的創新為行業參與者提供了充滿希望的機會。在更深入的遺傳見解和生物標記識別的推動下，個人化醫療為客製化治療開闢了新途徑，推動了患者治療結果和市場擴張。

主要市場統計
基準年[2023] 73.4億美元
預測年份 [2024] 79.7億美元
預測年份 [2030] 131.8億美元
複合年成長率（%） 8.71%

神經診斷市場的挑戰包括與尖端診斷成像設備相關的高成本以及缺乏熟練的專業人員。監管障礙和神經系統疾病的複雜性常常會延遲產品開發和核准流程，造成額外的障礙。為了克服這些挑戰，公司應專注於開發具有成本效益的診斷工具並投資於培訓計劃以縮小專業知識差距。此外，與學術機構的聯合研究將有助於發現新的生物標記和治療藥物，並有望擴大市場。創新成熟的領域包括即時監測解決方案和數位醫療技術的整合，以促進早期診斷和遠端監測，在遠端醫療環境中特別有用。

儘管存在一些障礙，醫療保健支出的持續成長和患者意識的提高表明神經診斷市場前景廣闊。對於公司來說，透過利用巨量資料分析和機器學習來提高診斷準確性和患者分層來保持領先地位仍然至關重要。向神經系統疾病診斷不足的新興市場擴張可能會進一步支持成長。因此，策略夥伴關係和研發投資對於滿足全球對神經醫療解決方案不斷成長的需求並提供有效的解決方案同時保持競爭力至關重要。

市場動態：快速發展的神經診斷市場的關鍵市場洞察

供需的動態交互作用正在改變神經診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球神經系統疾病增加
    • 提高患者對早期診斷和有效治療的認知
    • 擴大創新診斷技術的採用
  • 市場限制因素
    • 與神經診斷設備相關的高成本
  • 市場機會
    • 神經退化性疾病診斷的基因組學和蛋白​​質組學進展
    • 正在進行的神經系統疾病臨床試驗
  • 市場挑戰
    • 缺乏熟練的醫療保健專業人員

波特五力：駕馭神經診斷藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對神經診斷藥物市場的影響

外部宏觀環境因素在塑造神經診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解神經診斷藥物市場的競爭狀況

神經診斷市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣神經診斷市場供應商績效評估

FPNV定位矩陣是評估神經診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪神經診斷市場的成功之路

神經診斷市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球神經系統疾病發生率增加
      • 患者擴大尋求疾病的早期診斷以進行有效治療
      • 擴大創新診斷技術的引進
    • 抑制因素
      • 與神經診斷設備相關的高成本
    • 機會
      • 基因組學和蛋白​​質組學在神經退化性疾病診斷的進展
      • 神經系統疾病的臨床試驗正在進行中
    • 任務
      • 缺乏熟練的醫療保健專業人員
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章神經診斷市場：依產品

  • 臨床檢測設備
    • NGS設備
    • PCR裝置
    • 桑格音序器
  • 診斷和影像系統
    • 血管造影術系統
    • CT掃描儀
    • 腦電圖系統
    • 肌電圖儀
    • 腦磁圖裝置
    • 核磁共振系統
    • 正子斷層掃描儀
    • 超音波影像成像系統
  • 試劑/耗材
    • 抗體
    • 緩衝
    • 酵素、蛋白質、胜肽
    • 媒體與血清
    • 探測
    • 溶劑

第7章依適應症分類的神經診斷藥物市場

  • 癲癇
  • 頭痛症
  • 神經退化性疾病
  • 睡眠障礙
  • 中風

第8章神經診斷市場：依最終用戶分類

  • 門診治療中心
  • 診斷實驗室和影像中心
  • 醫院/診所
  • 神經中樞

第9章北美和南美神經診斷藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區神經診斷市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的神經診斷藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories Inc.
  • Adeor Medical AG
  • Advanced Brain Monitoring, Inc.
  • Canon Medical Systems USA, Inc.
  • DEYMED Diagnostic sro
  • F. Hoffmann-La Roche Ltd.
  • GE Healthcare
  • Koninklijke Philips NV
  • Lifelines Neuro Company, LLC
  • Medtronic PLC
  • Mitsar Co., Ltd.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-030226489D71

The Neurodiagnostics Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.97 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 13.18 billion by 2030.

The neurodiagnostics market entails the development and utilization of diagnostic tools and tests to assess and monitor neurological disorders. As the prevalence of neurological conditions like Alzheimer's, epilepsy, and Parkinson's disease continues to rise, the need for precise diagnostic modalities intensifies. The market encompasses various applications such as neuroimaging, in-vitro diagnostics, and neuro-informatics, catering to healthcare facilities, diagnostic laboratories, and academic research centers. Key growth drivers include the increasing geriatric population, advancements in neuroimaging technologies, and heightened demand for minimally invasive diagnostics. Innovations in AI-driven imaging analysis and portable EEG devices present promising opportunities for industry players. Personalized medicine, driven by deeper genetic insights and biomarker identification, is opening up new avenues for tailored treatments, advancing both patient outcomes and market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 7.34 billion
Estimated Year [2024] USD 7.97 billion
Forecast Year [2030] USD 13.18 billion
CAGR (%) 8.71%

Challenges within the neurodiagnostics market include high costs associated with cutting-edge imaging equipment and a scarcity of skilled professionals. Regulatory hurdles and the complexity of neurological disorders often delay product development and approval processes, posing further barriers. To overcome these challenges, businesses should focus on developing cost-effective diagnostic tools and investing in training programs to bridge the expertise gap. Collaborative research with academic institutions could also expedite the discovery of novel biomarkers and therapeutics, enhancing market growth. Areas ripe for innovation include real-time monitoring solutions and the integration of digital health technologies, which can facilitate early diagnosis and remote monitoring, particularly valuable in telemedicine settings.

Despite some hurdles, the continuous growth in healthcare expenditure, coupled with increased patient awareness, suggests a promising outlook for the neurodiagnostics market. It remains pivotal for companies to stay ahead by leveraging big data analytics and machine learning to refine diagnostic accuracy and patient stratification. Expanding reach in emerging markets, where neurological disorders are underdiagnosed, could further bolster growth. Thus, strategic partnerships and investments in R&D are critical to harness the full potential of neurodiagnostics innovations, ensuring companies remain competitive and effective in addressing the evolving global demands for neurological healthcare solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurodiagnostics Market

The Neurodiagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidences of neurological disorders worldwide
    • Growing awareness among patients for early disease diagnosis for effective treatment
    • Growing adoption of innovative diagnostic technologies
  • Market Restraints
    • High cost associated with the neurodiagnostic devices
  • Market Opportunities
    • Advances in genomics and proteomics for neurodegenerative disorders diagnosis
    • Ongoing clinical trials for neurological disease
  • Market Challenges
    • Limited availability of skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Neurodiagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurodiagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurodiagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurodiagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurodiagnostics Market

A detailed market share analysis in the Neurodiagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurodiagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurodiagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurodiagnostics Market

A strategic analysis of the Neurodiagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurodiagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Adeor Medical AG, Advanced Brain Monitoring, Inc., Canon Medical Systems USA, Inc., DEYMED Diagnostic s.r.o., F. Hoffmann-La Roche Ltd., GE Healthcare, Koninklijke Philips N.V., Lifelines Neuro Company, LLC, Medtronic PLC, Mitsar Co., Ltd., Natus Medical Incorporated, Nihon Kohden Corporation, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Neurodiagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Clinical Testing Instrument, Diagnostic & Imaging System, and Reagent & Consumable. The Clinical Testing Instrument is further studied across NGS Instrument, PCR Instrument, and Sanger Sequencer. The Diagnostic & Imaging System is further studied across Angiography System, CT Scanner, EEG System, EMG Device, MEG Device, MRI System, PET Scanner, and Ultrasound Imaging System. The Reagent & Consumable is further studied across Antibody, Buffer, Enzyme, Protein, & Peptide, Media & Sera, Probe, and Solvent.
  • Based on Indication, market is studied across Epilepsy, Headache Disorder, Neurodegenerative Diseases, Sleep Disorder, and Stroke.
  • Based on End User, market is studied across Ambulatory Care Center, Diagnostic Laboratory & Imaging Center, Hospital & Clinic, and Neurology Center.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of neurological disorders worldwide
      • 5.1.1.2. Growing awareness among patients for early disease diagnosis for effective treatment
      • 5.1.1.3. Growing adoption of innovative diagnostic technologies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the neurodiagnostic devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in genomics and proteomics for neurodegenerative disorders diagnosis
      • 5.1.3.2. Ongoing clinical trials for neurological disease
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of skilled healthcare professionals
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neurodiagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Clinical Testing Instrument
    • 6.2.1. NGS Instrument
    • 6.2.2. PCR Instrument
    • 6.2.3. Sanger Sequencer
  • 6.3. Diagnostic & Imaging System
    • 6.3.1. Angiography System
    • 6.3.2. CT Scanner
    • 6.3.3. EEG System
    • 6.3.4. EMG Device
    • 6.3.5. MEG Device
    • 6.3.6. MRI System
    • 6.3.7. PET Scanner
    • 6.3.8. Ultrasound Imaging System
  • 6.4. Reagent & Consumable
    • 6.4.1. Antibody
    • 6.4.2. Buffer
    • 6.4.3. Enzyme, Protein, & Peptide
    • 6.4.4. Media & Sera
    • 6.4.5. Probe
    • 6.4.6. Solvent

7. Neurodiagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Epilepsy
  • 7.3. Headache Disorder
  • 7.4. Neurodegenerative Diseases
  • 7.5. Sleep Disorder
  • 7.6. Stroke

8. Neurodiagnostics Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Care Center
  • 8.3. Diagnostic Laboratory & Imaging Center
  • 8.4. Hospital & Clinic
  • 8.5. Neurology Center

9. Americas Neurodiagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neurodiagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neurodiagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc.
  • 2. Adeor Medical AG
  • 3. Advanced Brain Monitoring, Inc.
  • 4. Canon Medical Systems USA, Inc.
  • 5. DEYMED Diagnostic s.r.o.
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. GE Healthcare
  • 8. Koninklijke Philips N.V.
  • 9. Lifelines Neuro Company, LLC
  • 10. Medtronic PLC
  • 11. Mitsar Co., Ltd.
  • 12. Natus Medical Incorporated
  • 13. Nihon Kohden Corporation
  • 14. Siemens Healthineers AG
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. NEURODIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEURODIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NEURODIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEURODIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEURODIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEURODIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NGS INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ANGIOGRAPHY SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY CT SCANNER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EEG SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EMG DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MEG DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PET SCANNER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ULTRASOUND IMAGING SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY BUFFER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY ENZYME, PROTEIN, & PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY MEDIA & SERA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY PROBE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SOLVENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HEADACHE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY SLEEP DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORY & IMAGING CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEURODIAGNOSTICS MARKET SIZE, BY NEUROLOGY CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES NEURODIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA NEURODIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY CLINICAL TESTING INSTRUMENT, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC & IMAGING SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY REAGENT & CONSUMABLE, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM NEURODIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 292. NEURODIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 293. NEURODIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023